Budapest, Hungary

Ágnes Proszenyák

USPTO Granted Patents = 6 

 

Average Co-Inventor Count = 13.4

ph-index = 1

Forward Citations = 8(Granted Patents)


Location History:

  • Molnári, HU (2017 - 2019)
  • Budapest, HU (2019 - 2020)

Company Filing History:


Years Active: 2017-2020

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Ágnes Proszenyák: Innovator in Pharmaceutical Chemistry

Introduction

Ágnes Proszenyák is a notable inventor based in Budapest, Hungary. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that serve as pro-apoptotic agents. With a total of six patents to his name, his work has implications for treating various medical conditions.

Latest Patents

Among his latest patents are innovative formulations that include bicyclic derivatives and amino acid derivatives. The bicyclic derivatives patent details a process for their preparation and pharmaceutical compositions containing them. These compounds are defined by specific formulas and are useful in treating conditions that require a pro-apoptotic agent. Similarly, his patent on amino acid derivatives outlines a process for their preparation and medicinal products that can aid in treating conditions necessitating a pro-apoptotic agent.

Career Highlights

Throughout his career, Ágnes Proszenyák has worked with prominent companies in the pharmaceutical industry, including Les Laboratoires Servier and Vernalis Limited. His experience in research and development has allowed him to contribute to significant advancements in medicinal chemistry.

Collaborations

He has collaborated with esteemed colleagues such as András Kotschy and Szabolcs Sipos, further enhancing the impact of his work in the field.

Conclusion

Ágnes Proszenyák's innovative contributions to pharmaceutical chemistry and his dedication to developing effective medicinal products underscore his importance as an inventor. His work continues to influence the treatment of conditions requiring pro-apoptotic agents.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…